Search
Sapropterin
go.drugbank.com/drugs/DB00360ApprovedInvestigationaltryptophan to 5-hydroxytryptophan via tryptophan hydroxylase. … It is also essential in the conversion of phenylalanine to tyrosine by the enzyme phenylalanine-4-hydroxylase; the conversion of tyrosine to L-dopa by the enzyme tyrosine hydroxylase; and conversion of
Categories: P-glycoprotein inhibitors, Heterocyclic Compounds, 2-RingSynonyms: 2-Amino-6-(1,2-dihydroxypropyl)-5,6,7,8-tetrahydoro-4(1H)-pteridinone, (−)-(6R)-2-amino-6-((1R,2S)-1,2-dihydroxypropyl)-5,6,7,8-tetrahydro-4(3H)-pteridinoneBelimumab
go.drugbank.com/drugs/DB08879ApprovedInvestigational[L42630] Belimumab was first approved by the FDA on March 9, 2011,[A251495] making it the newest drug to be approved for the treatment of SLE in more than 50 years. … It is produced by recombinant DNA technology in a murine cell (NS0) expression system.
Categories: Decreased B Lymphocyte Activation, B Lymphocyte Stimulator-specific InhibitorProducts: BENLYSTA 200 MG / 1 ML, BENLYSTA SUBCUTÁNEO 200 MG / 1 MLPembrolizumab
go.drugbank.com/drugs/DB09037ApprovedInvestigationalIt was generated by grafting the variable sequences of a very high-affinity mouse antihuman PD-1 antibody onto a human IgG4-kappa isotype containing a stabilizing S228P Fc mutation. … [F136] It was developed by Merck & Co and first approved for the treatment of metastatic malignant melanoma by the FDA on September 4, 2014,[L2954] becoming the first approved therapy against PD-1.
Categories: PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors, PD-1/PD-L1 (Programmed cell death protein 1/death ligand 1) inhibitorsProducts: KEYTRUDA® 100 MG, KEYTRUDA 100 MG/4 ML IV INFUZYONLUK COZELTI İÇEREN FLAKON, 1 ADETIbrutinib
go.drugbank.com/drugs/DB09053ApprovedInvestigationalIt is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. … Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase.
Categories: Heterocyclic Compounds, 1-Ring, Cytochrome P-450 SubstratesSynonyms: 1-[(3R)-3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-onePentetic acid
go.drugbank.com/drugs/DB14007ApprovedInvestigational[A32501] It is currently considered, in all the dosage forms, as a member of the list of approved inactive ingredients for drug products by the FDA. … [L2242] DPTA was developed by the pharmaceutical company CIS US and FDA approved on April 14, 2004.[L1469]
Categories: Compounds used in a research, industrial, or household settingSynonyms: DTP-ABortezomib
go.drugbank.com/drugs/DB00188ApprovedInvestigationalBortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. … [A204083] The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and
Categories: Heterocyclic Compounds, 1-Ring, P-glycoprotein substrates with a Narrow Therapeutic IndexSynonyms: [(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl)amino]propyl]amino]butyl]boronic Acid, N-[(1R)-1-(DIHYDROXYBORYL)-3-methylbutyl]-N-(pyrazin-2-ylcarbonyl)-L-phenylalaninamideKB3305
go.drugbank.com/drugs/DB06349ExperimentalKB3305 is an investigational liver selective antagonist for the glucocorticoid receptor, developed by Karo Bio for the treatment of Type 2 Diabetes.
Categories: 17-KetosteroidsSynonyms: 3.BETA.,5.BETA.,7.ALPHA.,12.ALPHA.)-7,12-DIHYDROXY-3-(2-((4-((11.BETA.,17.BETA.)-17-HYDROXY-3-OXO-17-(1-PROPYN-1-YL)ESTRA-4,9-DIEN-11-YL)PHENYL)METHYLAMINO)ETHOXY)CHOLAN-24-OIC ACID, CHOLAN-24-OIC ACID, 7,12-DIHYDROXY-3-(2-((4-((11.BETA.,17.BETA.)-17-HYDROXY-3-OXO-17-(1-PROPYN-1-YL)ESTRA-4,9-DIEN-11-YL)PHENYL)METHYLAMINO)ETHOXY)-, (3.BETA.,5.BETA.,7.ALPHA.,12.ALPHA.)-Omalizumab
go.drugbank.com/drugs/DB00043ApprovedInvestigationalOmalizumab is a recombinant DNA-derived humanized monoclonal antibody directed against human immunoglobulin E (IgE). … [L50482] It is used to treat a range of immune and inflammatory conditions, including allergies, urticaria, and asthma.[A263507]
Products: XOLAIR ® 150 MG, XOLAIR 150 MG/ML ENJEKSIYONLUK COZELTI İÇEREN KULLANIMA HAZIR ENJEKTÖR, 1 ADETTestosterone cypionate
go.drugbank.com/drugs/DB13943ApprovedInvestigationalIt was developed by the company Pharmacia and Upjohn and FDA approved on July 25, 1979. … Testosterone cypionate is a synthetic derivative of testosterone in the form of an oil-soluble 17 (beta)-cyclopentylpropionate ester.
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesProducts: DEPO-TESTOSTERONE STERILE SOLUTION 100 mg/ml, DEPO-TESTOSTERONE STERILE SOLUTION 200 mg/mlOxygen
go.drugbank.com/drugs/DB09140ApprovedInvestigationalVet approvedOxygen is an element displayed by the symbol O, and atomic number 8. It is an essential element for human survival. Decreased oxygen levels may be treated with medical oxygen therapy. … Treatment with oxygen serves to increase blood oxygen levels and also exerts a secondary effect of decreasing blood flow resistance in the diseased lung, leading to decreased cardiovascular workload in
Mixtures: Carbon Dioxide 1% W Oxygen, Donopa 50%/50% v/v Gas zur medizinischen Anwendung, druckverdichtetProducts: Oxygen Size M, Oxygen/Nitrogen 10/90